Last reviewed · How we verify
NCT03131232: Empa
The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be Investigated
trial in Diabetes Mellitus, Type 2 in 46 participants. Status unknown.
1 August 2017
Quick facts
| Lead sponsor | RWTH Aachen University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 46 |
| Start date | 10 December 2015 |
| Primary completion | 1 August 2017 |
| Estimated completion | 31 December 2017 |
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
RWTH Aachen University
Who can join
18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In summary, the registry should provide novel insight into potential mechanisms of cardiovascular risk reduction in patients treated with Empagliflozin with an indication of intensified glucose lowering therapy based on their HbA1c level.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function.
Puetz A, Artati A, Adamski J, Schuett K, et al · · 2022 · cited 14× · PMID 34811951 · DOI 10.1002/ehf2.13713
Verify or expand the search:
- PubMed search for NCT03131232
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other RWTH Aachen University trials
Trials by the same sponsor.
- NCT06390384 — Prevention Programme for Improvement of Well-being and Level of Participation in Adolescents With Enhanced Psychiatric B · NA · not yet recruiting
- NCT07322796 — Smoking Cessation Before Bronchoscopy or CT-guided Puncture · recruiting
- NCT04996914 — Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma · NA · not yet recruiting
- NCT07053956 — Impact of Chewing Gum on FeNO Levels in Patients With Bronchial Asthma · NA · completed
- NCT07140536 — The Impact of Treadmills and Cooler Environments for Office Workplaces on Ergonomics, Heating Energy Requirements, Perfo · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03131232 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RWTH Aachen University
- Last refreshed: 27 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03131232.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing